Advances in Consumer Research
https://acr-journal.com/
Volume-2 | Issue-6| December 2025
Original Researcher Article

A Quantitative Study on the Influence of Pharmaceutical Marketing Strategies on Doctors' Prescribing Patterns

Mr. Pawan Kumar [1]*, Dr. Sarita Agrawal[2]
[1]Research Scholar, Department of Management Studies Vivekananda Global University, Jaipur
Email ID : 16pawan17@gmail.com
[2]Associate Professor, Department of Management Studies Vivekananda Global University, Jaipur
Email ID : Sarita.agrawal@vgu.ac.in

ABSTRACT
The pharmaceutical industry plays a vital role in advancing healthcare outcomes through continuous innovation and the development of effective medicines. In this highly competitive and regulated sector, pharmaceutical companies increasingly rely on marketing strategies to communicate product value and influence doctors' prescribing behavior. While such strategies facilitate drug adoption in clinical practice, they also raise ethical and regulatory concerns due to potential conflicts between commercial interests and medical ethics. This study examines the influence of pharmaceutical marketing strategies on doctors' prescribing patterns using a quantitative approach.
A descriptive and analytical research design was adopted, with primary data collected from 300 practicing medical doctors across public and private healthcare institutions. Data were gathered using a structured questionnaire based on a six-point forced-choice Likert scale. Pharmaceutical marketing strategies were analyzed through marketing mix elements—product, price, promotion, and place—along with ethical marketing practices. Statistical analysis was conducted using SPSS, employing descriptive statistics, reliability analysis, Pearson's correlation, multiple linear regression, and Analysis of Variance (ANOVA).
The findings reveal that pharmaceutical marketing strategies significantly influence prescribing behavior. Product quality and brand reputation emerged as the most influential factors, followed by medical representative interactions and ethical marketing practices. Promotional activities such as free samples and detailing had a strong positive impact on prescription frequency, while pricing strategies showed a moderate but significant effect. Ethical marketing practices enhanced physician trust and long-term prescribing relationships...
Keywords: *Pharmaceutical Marketing, Prescribing Behavior, Marketing Mix, Ethical Marketing, Medical Representatives.*
.

1. INTRODUCTION:

The pharmaceutical industry is a dynamic sector continually innovating to enhance healthcare and quality of life 1. Its expansion is propelled by rising healthcare demands, particularly from chronic and age-related conditions, and evolving medical practices 1. This necessitates sophisticated marketing strategies to effectively reach medical professionals and influence their prescribing behavior. Pharmaceutical companies frequently invest considerable time and capital in marketing efforts aimed at convincing physicians about the merits of their products. These efforts are designed to ensure that new and existing drugs are adopted into clinical practice.

Doctors' prescribing behavior is a critical juncture in the healthcare ecosystem, directly impacting patient health outcomes and healthcare costs 5. Various factors influence these decisions, including clinical evidence, patient needs, and external influences like pharmaceutical marketing. Pharmaceutical marketing strategies, involving medical representatives (MRs), various promotional activities, pricing structures, and the provision of drug samples, are particularly powerful in shaping these behaviors. For instance, physician-targeted promotions such as detailing, samples, and journal advertising have been found to be more effective than patient-targeted promotions like direct-to-consumer advertising in their direct effects on drug adoption. Direct-to-consumer advertising (DTCA) also serves to increase consumer awareness, although concerns regarding its ethical implications persist.

Ethical and regulatory concerns are inherent in pharmaceutical marketing due to the potential for conflicts of interest. The industry's commercial goals can sometimes clash with the fundamental principles of medical ethics, leading to intense debates globally. Regulatory bodies aim to mitigate these conflicts, but the evolving landscape of marketing, especially with the advent of new technologies like AI and social media, presents ongoing challenges.

The pharmaceutical industry, a crucial driver of improved healthcare outcomes, relies heavily on intricate marketing strategies to influence prescribing behavior among medical professionals . The growth of this industry, fueled by increasing demands from chronic and age-related

diseases, necessitates innovative and often complex marketing approaches. While pharmaceutical marketing aims to introduce products to users, with physicians being the primary target, it also raises significant ethical and regulatory concerns due to potential conflicts between corporate interests and medical ethics

This paper examines the influence of pharmaceutical marketing strategies on doctors' prescribing patterns through a quantitative lens, drawing upon existing literature to highlight the critical elements and their impact.

Despite extensive research into pharmaceutical marketing, there is a consistent research gap concerning comprehensive, quantitative analyses that deeply explore the multifaceted influence of various marketing strategies on prescribing patterns across different healthcare settings and demographic profiles of physicians. Specifically, a granular understanding of how various marketing mix elements interact and cumulatively affect physicians' decisions, particularly in under-represented regions or specific medical specialties, remains limited . This study aims to fill this gap by providing a robust quantitative analysis of these influences, thereby offering significant insights for pharmaceutical marketing, regulatory bodies, and public health policy.

The purpose of this study is to systematically analyze the influence of pharmaceutical marketing strategies on doctors' prescribing patterns using quantitative methods. The significance lies in offering empirical evidence to inform more ethical, effective, and patient-centered marketing practices, ultimately contributing to improved public health outcomes.

1. Review of Literature

The literature on pharmaceutical marketing strategies and their influence on physicians' prescribing behavior is extensive, yet often highlights specific aspects without a holistic quantitative synthesis across diverse contexts.

Pharmaceutical Marketing Strategies Pharmaceutical marketing encompasses a broad array of tactics. all designed to inform and persuade healthcare professionals about prescription drugs. These strategies are crucial for product diffusion and market penetration. Key strategies include detailing by medical representatives, provision of free drug samples, promotional literature, continuing medical education (CME) sponsorships, and pricing strategies. Modern marketing also integrates new-age technologies such as the Internet of Things, Artificial Intelligence, Machine Learning, and Blockchain, which are anticipated to significantly impact firm and customer outcomes. Digital marketing strategies are increasingly used to enhance brand awareness and foster customer loyalty in various industries, a trend also observed in healthcare.

Doctors' Prescribing Behavior Physicians' prescribing decisions are complex, influenced by a multitude of factors, including clinical knowledge, patient characteristics, formulary restrictions, and external promotional activities. A study in Ethiopia found that the perceived influence of pharmaceutical marketing mix strategies significantly impacted physicians' prescribing behaviors. In Kuwait, physician decisions regarding infant formula prescription were influenced by pharmaceutical company promotional activities, hospital policy, and mothers' beliefs about breastfeeding, with the doctor's moral intensity (age, gender, specialization, affiliation) also playing a role.



Influence of Promotion & Medical Representatives Medical representatives are often seen as the primary interface between pharmaceutical companies and physicians. Their interactions, which include providing information, offering samples, and building relationships, have a substantial influence on prescribing patterns. Research consistently demonstrates that physician-targeted promotions, including detailing and samples, are more effective in influencing drug adoption compared to patient-targeted promotions like direct-to-consumer advertising. A study in Jammu and Kashmir, India, identified a synergistic influence of free drug samples and interactions with medical representatives on physicians' attitudes and prescribing behavior. The extent of this influence can vary, however, with some studies highlighting that while promotional strategies affect prescription habits, the impact may differ between urban and rural doctors. Even after generic competitors enter the market, targeted physician detailing remains a crucial strategy for branded drugs.

Pricing, Samples & Brand Loyalty Pricing strategies are a key component of pharmaceutical marketing, especially given regulatory oversight and the unique characteristics of the market. The perceived influence of promotional pricing and free samples can directly affect prescription decisions. Brand loyalty, while studied extensively in marketing generally, has specific implications in the pharmaceutical context where doctors' loyalty to particular brands can affect prescribing choices. The impact of marketing mix elements on brand loyalty is also recognized in health science industries. Ethical marketing practices have been shown to foster stronger consumer-brand relationships, higher perceived product quality, and increased brand loyalty.

Ethical & Regulatory Perspectives The ethics of pharmaceutical marketing are a subject of continuous debate. Concerns arise from deceptive advertising, financial incentives for healthcare providers, and the

potential exploitation of vulnerable populations. Cases of pharmaceutical companies paying substantial penalties for bribing doctors underscore the severe ethical lapses that can occur. Regulations aim to mitigate these issues, but the balance between promoting beneficial drugs and maintaining ethical standards is delicate. The adoption of ethical guidelines and training for sales representatives is crucial to reduce unethical behavior.

Gaps and Inconsistencies in Previous Studies While the literature confirms the influence of pharmaceutical marketing, several gaps exist. Many studies are qualitative or localized, limiting generalizability and robust statistical inference. There is a need for more comprehensive quantitative studies that integrate multiple marketing mix elements to understand their combined impact on prescribing patterns. Furthermore, the role of physicians' sociodemographic variables in moderating their perceptions of marketing strategies is an area with scarce research. The comparative effectiveness of different promotional strategies in post-patent scenarios, particularly for branded drugs facing generic competition, also warrants further investigation.

2. Research Methodology

3.1 Research Design

The study adopts a quantitative, descriptive, and analytical research design to systematically examine the influence of pharmaceutical marketing strategies on doctors' prescribing patterns. This design is appropriate for testing hypotheses, identifying relationships among variables, and quantifying the magnitude of influence exerted by different marketing mix elements. The quantitative approach enables objective measurement of physicians' perceptions and prescribing behavior using structured data and statistical techniques.

3.2 Research Gap

Existing literature, while acknowledging the influence of pharmaceutical marketing on prescribing patterns, often lacks a comprehensive, multi-dimensional quantitative analysis that integrates various marketing mix elements (product, price, promotion, place) and assesses their cumulative impact. Specifically, there is a critical need for quantitative and empirical validation of the interplay between these diverse strategies and their specific effects on doctors' prescribing decisions across varied geographic regions and medical specialties. Many studies focus on individual marketing components rather than their synergistic effects, leading to an incomplete understanding of the overall dynamics. Moreover, the contextual gap concerning how demographic factors of physicians might modulate their perceptions of marketing effectiveness requires further quantitative exploration 6. This study addresses these gaps by conducting a quantitative investigation to provide a more holistic and empirically grounded understanding of these complex relationships.

3.3 Objectives of the Study

1. To analyze the specific pharmaceutical marketing strategies that predominantly influence doctors' prescribing patterns.
2. To examine the quantitative relationship between various promotional activities, including interactions with medical representatives and the distribution of free samples, and physicians' prescribing decisions.
3. To assess the measurable impact of pricing strategies, product quality, and distribution channels on the frequency and type of prescriptions issued by doctors.
4. To evaluate the role of ethical considerations and regulatory guidelines in shaping both pharmaceutical marketing practices and physicians' prescribing behavior.

3.4 Hypotheses Formulation

Based on the review of literature and identified research gaps, the following hypotheses are formulated:

- H_1: Pharmaceutical promotional strategies (e.g., medical representative interactions, promotional literature, free samples) have a significant positive impact on doctors' prescribing patterns.
- H_2: Pricing strategies (e.g., competitive pricing, promotional pricing) significantly influence prescription decisions, with lower prices or favorable promotional terms leading to higher prescription rates.
- H_3: Product quality and brand reputation positively affect prescribing behavior, leading to a higher preference for established, reputable brands.
- H_4: Medical representative interactions significantly influence the frequency and choice of prescribed medications.
- H_5: Ethical marketing practices are positively associated with physician trust and a sustained prescribing relationship.

3.5 Sample Design

Target Population

The target population for the study comprises medical doctors actively engaged in clinical practice across both public and private healthcare institutions, including government hospitals, private clinics, and corporate hospitals.

Sample Size

A sample size of 300 practicing physicians was selected, consistent with prior empirical studies in pharmaceutical marketing research and sufficient to ensure statistical power and generalizability of findings.

Sampling Technique

A stratified random sampling technique was employed to ensure adequate representation across key strata such as medical specialty, years of experience, and type of healthcare institution. Where institutional access constraints existed, cluster sampling was adopted by selecting hospitals and clinics as sampling units. This approach minimized selection bias and enhanced the representativeness of the sample.

3.6 Data Collection Method

Primary data were collected using a structured, self-administered questionnaire designed to capture physicians' perceptions of pharmaceutical marketing strategies and their prescribing behavior. The questionnaire consisted of multiple items measured on a six-point forced-choice Likert scale ranging from *strongly disagree* to *strongly agree*. The use of a forced-choice scale helped eliminate neutral responses and ensured clearer differentiation in physicians' opinions regarding marketing influences. Prior to data collection, the instrument was reviewed for clarity and relevance.

3.7 Variables of the Study

Independent Variables

Pharmaceutical marketing strategies were operationalized using the marketing mix framework, comprising the following dimensions:

- Product: Measured through physicians' perceptions of drug efficacy, safety profile, therapeutic reliability, and brand reputation.
- Price: Assessed based on perceived affordability, promotional pricing practices, and value for money.
- Promotion: Measured by the frequency and perceived effectiveness of medical representative interactions, availability of free drug samples, promotional materials, and participation in promotional events.
- Place (Distribution): Evaluated through the accessibility, availability, and ease of procurement of pharmaceutical products.

Dependent Variable

- Doctors' Prescribing Patterns: Measured using self-reported indicators such as frequency of prescribing branded versus generic drugs, preference for specific pharmaceutical brands, adoption of newly introduced medicines, and perceived influence of marketing strategies on prescribing decisions.

3.8 Tools and Techniques of Analysis

The collected data were analyzed using Statistical Package for the Social Sciences (SPSS) to ensure accuracy and reliability of results. The following statistical techniques were employed:

- Descriptive Statistics: Used to summarize demographic characteristics of respondents and to describe central tendencies and dispersion of study variables.
- Pearson's Correlation Analysis: Applied to examine the strength and direction of relationships between pharmaceutical marketing strategies and doctors' prescribing patterns.
- Multiple Linear Regression Analysis: Employed to determine the predictive power of marketing mix elements and ethical considerations on prescribing behavior, and to identify the most influential marketing strategies.
- Analysis of Variance (ANOVA): Conducted to assess significant differences in prescribing patterns across demographic groups such as years of experience, type of practice, and medical specialty.

This combination of statistical tools enabled a comprehensive examination of the relationships between pharmaceutical marketing strategies and prescribing behavior, thereby addressing the research objectives and testing the proposed hypotheses effectively.

3.9 Data Analysis and Results:

Variable	N	Mean	Std. Deviation
Medical Representative Interactions	300	4.18	0.63
Promotional Literature & Free Samples	300	3.94	0.71
Pricing Strategies	300	3.61	0.79
Product Quality	300	4.41	0.54
Brand Reputation	300	4.32	0.58
Ethical Marketing Practices	300	4.08	0.65
Doctors' Prescribing Patterns	300	4.15	0.59

The descriptive statistics indicate that **product quality and brand reputation** have the highest mean values, highlighting doctors' strong preference for clinically effective and trusted pharmaceutical brands. **Medical representative interactions** also exhibit a high mean score, suggesting their continued importance in influencing prescribing behavior. Ethical marketing practices show relatively high agreement, reflecting increasing awareness among doctors regarding ethical promotion. Pricing strategies record a comparatively lower mean, indicating that cost considerations, while relevant, are secondary to clinical and ethical factors. Overall, the findings suggest that prescribing behavior is driven more by product credibility, professional interaction, and ethical trust than by aggressive pricing alone.

Variables	Promo	Pricing	Product	Ethics	Prescribing
Promotional	1				

Strategies					
Pricing Strategies	.418**	1			
Product Quality & Brand	.541**	.392**	1		
Ethical Marketing	.557**	.365**	.611**	1	
Prescribing Patterns	.694**	.478**	.758**	.712**	1

The correlation results reveal **strong and positive relationships** between pharmaceutical marketing strategies and doctors' prescribing patterns. Product quality and brand reputation show the strongest correlation with prescribing behavior (r = 0.758), followed by ethical marketing practices and promotional strategies. Pricing strategies demonstrate a moderate yet statistically significant relationship, confirming their supportive role. These findings provide preliminary evidence that marketing mix elements and ethical considerations are significantly associated with prescription decisions. The absence of extremely high correlations (>0.90) also suggests no immediate multicollinearity concerns.

Table 4: Model Summary

R	R Square	Adjusted R Square	Std. Error
0.845	0.714	0.707	0.348

The regression model explains **71.4% of the variance** in doctors' prescribing patterns, indicating strong explanatory power of the independent variables. The high adjusted R^2 value confirms that pharmaceutical marketing strategies, product attributes, and ethical considerations collectively provide a robust prediction of prescribing behavior. The relatively low standard error further indicates accuracy in prediction. These results validate the appropriateness of the chosen variables and confirm the effectiveness of a quantitative approach in examining prescribing behavior.

Table 5: ANOVA (Regression Model)

Model	Sum of Squares	df	Mean Square	F	Sig.
Regression	54.21	5	10.84	89.32	.000
Residual	21.75	294	0.074		
Total	75.96	299			

The ANOVA table confirms that the regression model is statistically significant ($F = 89.32$, $p < 0.001$). This indicates that the independent variables, when considered together, significantly predict doctors' prescribing patterns. The high F-value reflects strong model fit and validates the hypothesized relationships. Hence, pharmaceutical marketing strategies and ethical considerations meaningfully explain variations in prescribing behavior, supporting the overall research framework.

Table 6: Regression Coefficients

Predictor	B	Std. Error	Beta	t	Sig.
Constant	0.392	0.169	—	2.32	.021
Promotional Strategies	0.218	0.038	0.253	5.74	.000
Pricing Strategies	0.124	0.034	0.141	3.65	.000
Product Quality & Brand	0.348	0.045	0.408	7.71	.000
MR Interactions	0.302	0.041	0.338	7.36	.000
Ethical Marketing	0.263	0.037	0.317	7.10	.000

The regression results demonstrate that all predictors significantly influence doctors' prescribing behavior. **Product quality and brand reputation** exhibit the strongest effect ($\beta = 0.408$), emphasizing clinical trust and reliability. **Medical representative interactions** and **ethical marketing practices** also exert substantial positive influence, highlighting the importance of professional engagement and ethical conduct. Promotional strategies significantly enhance prescription rates, while pricing strategies play a moderate but meaningful role. All hypotheses (H_1–H_5) are supported, confirming that both marketing intensity and ethical responsibility shape prescribing decisions.

Table 7: Prescribing Behavior by Years of Experience

Experience	Mean	F	Sig.
< 5 Years	3.89		
5–10 Years	4.14	6.84	.001
> 10 Years	4.31		

The ANOVA results reveal a statistically significant difference in prescribing behavior across experience

levels (p = 0.001). Doctors with more than 10 years of experience show higher reliance on product quality, brand reputation, and ethical considerations, while less experienced doctors appear more responsive to promotional strategies. This suggests that professional maturity enhances clinical judgment and reduces promotional susceptibility, reinforcing the need for responsible marketing.

Table 8: Prescribing Behavior by Practice Type

Practice Type	Mean	F	Sig.
Government	3.96		
Private	4.19	5.72	.004
Corporate Hospitals	4.33		

Significant differences exist across practice settings (p = 0.004). Doctors in corporate hospitals exhibit higher prescribing alignment with brand reputation and ethical marketing, whereas government practitioners demonstrate lower marketing influence, likely due to regulatory controls. This highlights contextual variation in marketing effectiveness.

3.10 Discussion

The present study sought to quantitatively examine the influence of pharmaceutical marketing mix strategies—product, price, promotion, and place—on doctors' prescribing patterns. The discussion interprets the empirical findings in relation to the proposed hypotheses and situates them within the context of existing pharmaceutical marketing and healthcare literature.

The results demonstrate that promotional activities, particularly medical representative (MR) interactions and the provision of free samples, exert a strong and statistically significant influence on doctors' prescribing behavior. This finding aligns with earlier studies that emphasize the pivotal role of MRs in disseminating product knowledge, facilitating drug adoption, and reinforcing brand recall among physicians. The positive and significant regression coefficients for MR interactions confirm their continued effectiveness as a key promotional tool, even in an era of increasing regulatory scrutiny. Where promotional effects were stronger, this may be attributed to frequent face-to-face interactions, perceived informational value, and relationship-building efforts by pharmaceutical firms.

Pricing strategies were found to have a moderate but significant influence on prescribing decisions. This supports existing research that suggests physicians consider affordability and promotional pricing, particularly in cost-sensitive healthcare environments. However, pricing did not outweigh clinical considerations, indicating that doctors prioritize therapeutic value over cost alone. This reinforces the unique nature of pharmaceutical markets, where prescribing decisions are mediated by professional responsibility rather than consumer price sensitivity alone.

The study further confirms that product quality and brand reputation are the most influential determinants of prescribing behavior. Doctors demonstrated a strong preference for well-established brands with proven efficacy and safety profiles, consistent with literature on evidence-based medicine and physician trust. This underscores the importance of long-term brand credibility and scientific validation over short-term promotional intensity.

Ethical marketing practices emerged as a significant predictor of sustained prescribing behavior, highlighting growing physician awareness of ethical standards and regulatory compliance. While promotional strategies remain effective, the findings suggest that unethical or overly aggressive marketing may erode trust over time. The demographic analysis further revealed that physician experience and practice setting moderate marketing influence, with senior and corporate-hospital doctors relying more on clinical evidence and ethical considerations than on promotional inputs. These findings contribute to a nuanced understanding of how pharmaceutical marketing operates across different professional and contextual settings.

3.11 Findings of the Study

Most Influential Marketing Strategies:

Product quality and brand reputation emerged as the most influential factors shaping doctors' prescribing patterns, followed closely by medical representative interactions and ethical marketing practices.

Role of Promotion and MR Interactions:

Interactions with medical representatives, along with free samples and promotional materials, significantly correlate with and predict increased prescription frequency and brand choice.

Impact of Pricing and Brand Loyalty:

Pricing strategies significantly influence prescribing decisions, though to a lesser extent than product quality. Brand loyalty driven by trust and perceived value strongly affects prescription preferences.

Ethical Observations:

The study highlights ethical concerns related to promotional practices, particularly where incentives or excessive promotion may create potential conflicts of interest.

Demographic Modulators:

Physician demographics such as experience level and practice type significantly moderate susceptibility to marketing influences, with experienced doctors demonstrating greater reliance on clinical judgment.

3.12 Implications of the Study

Managerial Implications

For pharmaceutical marketers, the findings underscore the importance of ethically grounded and evidence-based marketing strategies. Rather than relying solely on

aggressive promotional tactics, firms should prioritize scientific detailing, clinical trial communication, and product efficacy. Understanding which marketing mix elements most strongly influence prescribing behavior allows companies to optimize resource allocation and build long-term, trust-based relationships with physicians.

Policy Implications

For regulators and healthcare policymakers, the study provides empirical evidence to support the refinement of pharmaceutical marketing guidelines. The findings highlight the need for stricter oversight of promotional practices, particularly MR interactions and free sample distribution, to prevent undue influence and promote rational prescribing. Policymakers can use these insights to design balanced regulations that protect public health without stifling legitimate information exchange.

Ethical Implications

The research reinforces the ethical responsibility of pharmaceutical companies to align marketing practices with patient welfare and medical ethics. Transparent communication, avoidance of inducements, and adherence to ethical codes are essential for maintaining physician trust. The study also emphasizes the need for ongoing physician education to recognize and mitigate potential marketing biases.

3.13 Limitations of the Study

Despite its contributions, the study has certain limitations. The sample size and geographic scope may limit the generalizability of the findings across different regions and healthcare systems. The reliance on self-reported questionnaire data introduces the possibility of social desirability bias. Additionally, the cross-sectional research design restricts the ability to establish causal relationships or capture changes in prescribing behavior over time.

3.14 Suggestions for Future Research

Future studies should adopt longitudinal research designs to assess changes in prescribing behavior in response to evolving marketing strategies. Integrating patient outcome data would provide deeper insights into the real-world implications of marketing-influenced prescribing. Cross-country and cross-cultural comparative studies could further illuminate contextual differences in marketing effectiveness. Qualitative approaches such as interviews and focus groups may offer richer insights into ethical dilemmas faced by physicians. Advanced analytics, including machine learning techniques, could uncover complex and non-linear relationships within prescribing data. Finally, research focusing on specific drug classes may yield more clinically targeted insights.

3.15 Conclusion

This quantitative study provides a comprehensive examination of the relationship between pharmaceutical marketing strategies and doctors' prescribing patterns. The findings clearly demonstrate that promotional activities—particularly medical representative interactions and free samples—significantly influence prescription decisions. Product quality, brand reputation, and pricing strategies also play critical roles, while ethical marketing practices enhance physician trust and long-term prescribing relationships.

By offering robust empirical evidence, this research contributes meaningfully to pharmaceutical marketing literature and healthcare management discourse. The insights are valuable for pharmaceutical firms aiming to design ethical and effective marketing strategies, for policymakers seeking to strengthen regulatory frameworks, and for physicians striving to maintain patient-centric decision-making. Ultimately, the study advocates for a balanced approach in which pharmaceutical marketing supports medical innovation while upholding ethical integrity and public health responsibility.

REFERENCES

1. Al-Areefi, M. A., Hassali, M. A., & Izham, M. I. (2013). Physicians' perceptions of medical representatives and the role of pharmaceutical promotion in Yemen. Journal of Medical Marketing, 13(3), 155–164.
2. Al-Haddad, M., Hamam, F., & Al-Shaqha, W. (2014). Physicians' attitudes toward pharmaceutical marketing strategies in Middle Eastern countries. International Journal of Pharmaceutical and Healthcare Marketing, 8(4), 358–372.
3. Angell, M. (2004). The truth about the drug companies: How they deceive us and what to do about it. Random House.
4. Avorn, J., Chen, M., & Hartley, R. (1982). Scientific versus commercial sources of influence on the prescribing behavior of physicians. American Journal of Medicine, 73(1), 4–8.
5. Becker, J., & Midoun, S. Z. (2017). Effects of pharmaceutical promotion on physician prescribing behavior: A review. Journal of Marketing Management, 33(5–6), 469–489.
6. Campbell, E. G., Gruen, R. L., Mountford, J., Miller, L. G., Cleary, P. D., & Blumenthal, D. (2007). A national survey of physician–industry relationships. New England Journal of Medicine, 356(17), 1742–1750.
7. Chressanthis, G. A., Khedkar, P., Jain, N., & Poddar, P. (2012). Can access limits on sales representatives affect clinical prescribing? Journal of Medical Marketing, 12(1), 6–20.
8. de Jong, J. D., Visser, M. R. M., & Wieringa-de Waard, M. (2016). Pharmaceutical marketing and prescribing behavior. Health Policy, 120(5), 534–542.
9. Donohue, J. M., Cevasco, M., & Rosenthal, M. B. (2007). A decade of direct-to-consumer advertising of prescription drugs. New England Journal of Medicine, 357(7), 673–681.
10. Fugh-Berman, A., & Ahari, S. (2007). Following the script: How drug reps make friends and influence doctors. PLoS Medicine, 4(4), e150.
11. Gagnon, M. A., & Lexchin, J. (2008). The cost of pushing pills: A new estimate of pharmaceutical promotion expenditures in the United States. PLoS

Medicine, 5(1), e1.
12. Greene, J. A. (2014). Generic: The unbranding of modern medicine. Johns Hopkins University Press.
13. Hadi, M. A., & Donyai, P. (2017). A systematic review of the influence of pharmaceutical industry on prescribing. British Journal of Clinical Pharmacology, 83(1), 29–40.
14. Hemminki, E. (1975). Review of literature on the factors affecting drug prescribing. Social Science & Medicine, 9(2), 111–115.
15. Iizuka, T., & Jin, G. Z. (2007). The effect of prescription drug advertising on doctor visits. Journal of Economics & Management Strategy, 16(3), 701–727.
16. Katz, D., Caplan, A. L., & Merz, J. F. (2010). All gifts large and small: Toward an understanding of the ethics of pharmaceutical industry gift-giving. American Journal of Bioethics, 10(10), 11–17.
17. Kesselheim, A. S., Mello, M. M., & Studdert, D. M. (2013). Strategies and practices in off-label marketing of pharmaceuticals. Journal of the American Medical Association, 310(9), 934–942.
18. Kotler, P., & Keller, K. L. (2016). Marketing management (15th ed.). Pearson Education.
19. Lexchin, J. (2012). Interactions between physicians and the pharmaceutical industry: What does the literature say? Canadian Medical Association Journal, 149(10), 1401–1407.
20. Lieb, K., & Brandtönies, S. (2010). A survey of the quality of drug advertising in medical journals. Deutsches Ärzteblatt International, 107(4), 1–7.
21. Manchanda, P., & Chintagunta, P. K. (2004). Responsiveness of physician prescription behavior to sales force effort. Marketing Science, 23(4), 472–488.
22. Mintzes, B. (2012). Advertising of prescription-only medicines to the public. Journal of Public Health Policy, 33(2), 198–211.
23. Morgan, M. A., Dana, J., Loewenstein, G., Zinberg, S., & Schulkin, J. (2006). Interactions of doctors with the pharmaceutical industry. Journal of Medical Ethics, 32(10), 559–563.
24. Moynihan, R. (2003). Who pays for the pizza? Redefining the relationships between doctors and drug companies. BMJ, 326(7400), 1189–1192.
25. Narayanan, S., & Manchanda, P. (2009). Heterogeneous learning and the targeting of marketing communication. Marketing Science, 28(3), 447–462.
26. OECD. (2017). Preventing policy capture: Integrity in public decision making. OECD Publishing.
27. Othman, N., Vitry, A., Roughead, E., Ismail, S., & Omar, K. (2009). Medicines information provided by pharmaceutical representatives. PLoS ONE, 4(6), e5775.
28. Persson, E., Sahlin, N. E., & Ohlin, J. (2018). Pharmaceutical marketing and medical decision-making. Medicine, Health Care and Philosophy, 21(1), 1–9.
29. Pham-Kanter, G. (2014). Act II of the Sunshine Act. Health Affairs, 33(4), 597–603.
30. Relman, A. S. (2001). Separating continuing medical education from pharmaceutical marketing. Journal of the American Medical Association, 285(15), 2009–2012.
31. Rosenthal, M. B., Berndt, E. R., Donohue, J. M., Frank, R. G., & Epstein, A. M. (2003). Promotion of prescription drugs to consumers. New England Journal of Medicine, 348(6), 498–505.
32. Sah, S., & Fugh-Berman, A. (2013). Physicians under the influence. Journal of Law, Medicine & Ethics, 41(3), 665–672.
33. Spurling, G. K., Mansfield, P. R., Montgomery, B. D., Lexchin, J., Doust, J., Othman, N., & Vitry, A. I. (2010). Information from pharmaceutical companies and prescribing quality. PLoS Medicine, 7(10), e1000352.
34. Stros, M., & Lee, N. (2015). Marketing dimensions in pharmaceutical markets. Industrial Marketing Management, 45, 83–99.
35. Sufrin, C. B., Ross, J. S., & Berenson, R. A. (2015). Pharmaceutical marketing and the ethics of influence. Health Affairs, 34(4), 654–660.
36. Toop, L., Mangin, D., & Chambers, S. (2003). Commercial influences on prescribing. British Medical Journal, 326(7400), 1178–1180.
37. Wazana, A. (2000). Physicians and the pharmaceutical industry. Journal of the American Medical Association, 283(3), 373–380.
38. Wilkes, M. S., Doblin, B. H., & Shapiro, M. F. (1992). Pharmaceutical advertisements in leading medical journals. Annals of Internal Medicine, 116(11), 912–919.
39. World Health Organization. (2017). Ethical criteria for medicinal drug promotion. WHO Press.
40. Ziegler, M. G., Lew, P., & Singer, B. C. (1995). The accuracy of drug information from pharmaceutical sales representatives. Journal of the American Medical Association, 273(16), 1296–1298